Quality of life in Chronic Kidney Disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study

Perlman, Rachel L.; Finkelstein, Fredric O.; Liu, Lei; Roys, Erik; Kiser, Margaret; Eisele, George; Burrows-Hudson, Sally; Messana, Joseph M.; Levin, Nathan W.; Rajagopalan, Sanjay; Port, Friedrich K.; Wolfe, Robert A.; Saran, Rajiv

doi:10.1053/j.ajkd.2004.12.021

Cited by 356 publications

(309 citation statements)

References 27 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…These findings are in line with previous studies (Evans et al, 1985; Merkus et al, 1997; Perlman et al, 2005). Diabetic nephropathy is the primary cause of end‐stage renal disease requiring dialysis (Akizawa, 2010).…”

Section: Discussionsupporting

confidence: 93%

Periodontitis and health‐related quality of life in hemodialysis patients

Iwasaki

Borgnakke

Awano

et al. 2016

Clinical & Exp Dental Res

View full text Add to dashboard Cite

Periodontitis is common among dialysis patients. The current cross‐sectional study aimed to explore associations between periodontitis and health‐related quality of life (HRQoL) among hemodialysis patients. Data from 188 dentate patients undergoing hemodialysis between May and July 2008 at a medical center in Kitakyushu city, Japan, were analyzed while applying modified Centers for Disease Control and Prevention/American Academy of Periodontology periodontitis case definitions to categorize the participants into the following three groups: severe, moderate, and no/mild periodontitis, respectively. HRQoL was assessed by the Medical Outcomes Study 36‐Item Short Form Health Survey (SF‐36) where a higher score indicates better health status. Associations between periodontitis groups and the eight health domains of SF‐36 were evaluated using general linear models that were adjusted for age, sex, underlying cause of dialysis, duration of dialysis, comorbidities, serum biomarkers, body mass index, smoking status, and alcohol use. Among the 188 participants, 18 (9.6%) had severe periodontitis, 100 (53.2%) had moderate periodontitis, and the remaining 70 (37.2%) had no/mild periodontitis. Compared with the participants with no/mild periodontitis, those with severe periodontitis had worse scores in the following five of eight SF‐36 health scales: physical functioning, role physical, vitality, social functioning, and mental health (P < 0.05). The findings suggest an independent relationship between severe periodontitis and decreased HRQoL among dialysis patients.

show abstract

Section: Discussionsupporting

confidence: 93%

Periodontitis and health‐related quality of life in hemodialysis patients

Iwasaki

Borgnakke

Awano

et al. 2016

Clinical & Exp Dental Res

View full text Add to dashboard Cite

show abstract

“…Persons with CKD and ESRD have poorer healthrelated quality of life (HRQOL) compared with the general population (1)(2)(3)(4). In patients with ESRD, low HRQOL is associated with a higher risk of death and hospitalization (3)(4)(5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Predictors and Outcomes of Health–Related Quality of Life in Adults with CKD

Porter¹,

Lash²,

Xie³

et al. 2016

CJASN

121

130

View full text Add to dashboard Cite

Background and objectives Low health-related quality of life is associated with increased mortality in patients with ESRD. However, little is known about demographic and clinical factors associated with health-related quality of life or its effect on outcomes in adults with CKD.Design, settings, participants, & measurements Data from 3837 adult participants with mild to severe CKD enrolled in the prospective observational Chronic Renal Insufficiency Cohort and Hispanic Chronic Renal Insufficiency Cohort Studies were analyzed. Health-related quality of life was assessed at baseline with the Kidney Disease Quality of Life-36 and its five subscales: mental component summary, physical component summary, burden of kidney disease (burden), effects of kidney disease (effects), and symptoms and problems of kidney disease (symptoms). Low health-related quality of life was defined as baseline score .1 SD below the mean. Using Cox proportional hazards analysis, the relationships between low health-related quality of life and the following outcomes were examined: (1) CKD progression (50% eGFR loss or incident ESRD), (2) incident cardiovascular events, and (3) all-cause death.Results Younger age, women, low education, diabetes, vascular disease, congestive heart failure, obesity, and lower eGFR were associated with low baseline health-related quality of life (P,0.05). During a median follow-up of 6.2 years, there were 1055 CKD progression events, 841 cardiovascular events, and 694 deaths. Significantly higher crude rates of CKD progression, incident cardiovascular events, and all-cause death were observed among participants with low health-related quality of life in all subscales (P,0.05). In fully adjusted models, low physical component summary, effects, and symptoms subscales were independently associated with a higher risk of incident cardiovascular events and death, whereas low mental component summary was independently associated with a higher risk of death (P,0.05). Low health-related quality of life was not associated with CKD progression.Conclusions Low health-related quality of life across several subscales was independently associated with a higher risk of incident cardiovascular events and death but not associated with CKD progression.

show abstract

“…However, the lower limit of this Hb range (10 g dL ) 1 ) is lower than that in current guidelines (11 g dL )1 ) [19], and it is unknown whether targeting to a higher Hb concentration will result in reductions in the number of subjects achieving the Hb target and/or in increases in darbepoetin alfa dose requirements. Therefore, the primary aim of this study was to determine whether darbepoetin alfa administered QM could safely and effectively maintain Hb concentrations ‡11 g dL )1 in subjects with CKD who were not receiving dialysis and whose Hb had previously been stabilized in the range of 11.0-13.0 g dL )1 with Q2W darbepoetin alfa therapy.…”

Section: Introductionmentioning

confidence: 85%

“…Subjects' Hb levels were to be stable, in the range of 11.0-13.0 g dL ) 1 . Following a screening assessment, eligible individuals were enrolled within 14 days and were switched from Q2W darbepoetin alfa to QM darbepoetin alfa.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

An open‐label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis

Agarwal

Silver

Reed

et al. 2006

Journal of Internal Medicine

View full text Add to dashboard Cite

Objective. To demonstrate the efficacy and safety of once-monthly (QM) darbepoetin alfa administration in maintaining haemoglobin (Hb) 11.0-13.0 g dL )1 in subjects with chronic kidney disease (CKD) not receiving dialysis and previously treated with darbepoetin alfa every other week (Q2W).Subjects. This open-label study enrolled subjects ‡18 years of age who had glomerular filtration rate ‡15 and £60 mL min )1 /1.73 m 2 , had Hb 11.0-13.0 g dL )1 , and were receiving Q2W darbepoetin alfa. Design. Subjects were switched to QM darbepoetin alfa therapy for 28 weeks; the QM dose was titrated to maintain Hb levels. Primary end-point:proportion of subjects maintaining Hb ‡11.0 g dL )1 during the final 8 weeks of the study (evaluation phase). Secondary end-points: Hb concentration during evaluation, darbepoetin alfa dose during the study, adverse events, laboratory parameters, and blood pressure. Results. The study enrolled 152 subjects (female 52%, white 64%). Mean Hb ‡11.0 g dL )1 during evaluation was achieved by 76% of the 150 subjects who received at least one dose of darbepoetin alfa [95% confidence interval (CI): 68%, 83%]. Mean (SD) Hb during evaluation was 11.71 (0.92) g dL )1 . Eighty-five per cent of 129 subjects who completed the study (95% CI: 78%, 91%) had Hb ‡11.0 g dL )1 during evaluation. The dose of darbepoetin alfa over the study period was median (95% CI) 124.4 lg (106.2, 140.0). Darbepoetin alpha administered QM was well tolerated in study subjects. Conclusion. Darbepoetin alpha administered QM maintained Hb in study subjects with CKD not receiving dialysis.

show abstract

Quality of life in Chronic Kidney Disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study

Cited by 356 publications

References 27 publications

Periodontitis and health‐related quality of life in hemodialysis patients

Periodontitis and health‐related quality of life in hemodialysis patients

Predictors and Outcomes of Health–Related Quality of Life in Adults with CKD

An open‐label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis

Contact Info

Product

Resources

About